Related Experiment Video

Updated: Apr 17, 2026

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

44.7K

[IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (studie IMPROVE-IT)]

Jindřich Špinar, Lenka Špinarová, Jiří Vítovec

    Vnitrni Lekarstvi
    |February 19, 2015
    PubMed

    Insights

    Adding ezetimibe to simvastatin significantly reduced major cardiovascular events in acute coronary syndrome patients with low LDL cholesterol. This combination therapy demonstrated a clear benefit over simvastatin alone.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Clinical Trials

    Background:

    • The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) investigated the addition of ezetimibe to simvastatin.
    • Focus on patients with acute coronary syndromes and low-density lipoprotein cholesterol (LDL-C) levels below 125 mg/dl.

    Purpose of the Study:

    • To evaluate the benefit of adding ezetimibe to simvastatin for reducing major cardiovascular (CV) events.
    • To compare the efficacy of simvastatin plus ezetimibe versus simvastatin plus placebo.

    Main Methods:

    • A randomized, double-blind clinical trial involving 18,144 patients with acute coronary syndrome.
    • Patients received either simvastatin monotherapy (target LDL-C < 70 mg/dl) or simvastatin plus ezetimibe.
    • Primary endpoint: composite of CV death, nonfatal myocardial infarction (MI), nonfatal stroke, unstable angina rehospitalization, or coronary revascularization.

    Main Results:

    • The combination therapy (simvastatin + ezetimibe) resulted in a 6.4% lower risk of the primary composite endpoint (p=0.016).
    • Significant reductions observed in heart attacks (13%) and non-fatal strokes (20%) with combination therapy.
    • No statistically significant difference in cardiovascular death between the groups. Number Needed to Treat (NNT) was approximately 50 over 7 years.

    Conclusions:

    • Combination treatment with simvastatin and ezetimibe offers a clear benefit for patients with acute coronary syndrome and low LDL-C.
    • This strategy effectively reduces major adverse cardiovascular events in this high-risk population.
    Abstract

    More Related Videos

    A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition04:53

    A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

    Published on: September 20, 2019

    11.5K
    A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis10:26

    A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

    Published on: June 2, 2015

    18.2K

    Related Concept Videos

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    1.9K
    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    435
    Clinical Trials: Overview01:11

    Clinical Trials: Overview

    Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
    5.5K
    Bioequivalence studies: Biowaivers01:13

    Bioequivalence studies: Biowaivers

    In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
    414
    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    622
    Antihypertensive Drugs: Direct Renin Inhibitors01:25

    Antihypertensive Drugs: Direct Renin Inhibitors

    The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
    1.9K